We’re on the eve of yet another wave of new treatments for severe asthma. Having recently adjusted clinical practice to accommodate multiple monoclonal antibody treatments, if results from Phase 2 studies of several small molecule drugs (SMDs) continue to show promise, treatment paradigms are likely to shift again.1,2 To understand more about SMDs currently in ...
Is it time to aim higher when it comes to severe asthma treatment?
Sponsored by Novartis Pharmaceuticals Australia Pty Ltd
6 Aug 2019